Clinical data for investigational SGLT2 inhibitor, empagliflozin*, demonstrates potential for oral treatment in type 2 diabetes
2 October 2012 | By Boehringer Ingelheim
Results of a pooled analysis...
List view / Grid view
News
Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies
2 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a large Phase III study and three pooled analyses of Phase III data presented at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting, which support Trajenta® (linagliptin) as effective and well-tolerated for patients with type…
Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer
1 October 2012 | By Roche
Updated survival results from the Phase III EMILIA study...
Merck to present new data for VICTRELIS® (boceprevir) and MK-5172 at The AASLD 2012 Annual Meeting
1 October 2012 | By Merck
New data from Phase III studies...
Boehringer Ingelheim’s novel project transfer program enables fast track to launch for biopharmaceuticals
1 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim Biopharmaceuticals has installed a fast track process transfer...
Head-to-head study of GSK’s Votrient® vs sunitinib in advanced renal cell carcinoma meets primary endpoint
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
Sanofi appoints Dr. Paul Chew, Chief Medical Officer and Head of Global Medical Affairs
1 October 2012 | By Sanofi
Sanofi is pleased to announce the appointment of Dr. Paul Chew...
Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer
1 October 2012 | By Roche
Final results from the Phase III HERA trial...
Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
New head of BASF unit Pharma Ingredients & Services
1 October 2012 | By BASF
As of October 1, Scott Thomson will assume the role of Senior Vice President...
Bristol-Myers Squibb appoints Frances Heller Senior Vice President, Business Development
28 September 2012 | By Bristol-Myers Squibb Company
Frances Heller will join as Senior VP, Business Development, on October 1...
Abbott’s HUMIRA® (adalimumab) receives U.S. FDA approval for the treatment of adult patients with moderate to severe ulcerative colitis
28 September 2012 | By Abbott
The U.S. FDA has approved HUMIRA®...
Avacta extends Pall Life Sciences’ Optim 1000 distribution agreement to include India
27 September 2012 | By kdm communications limited
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market...
Europe’s largest biopharmaceutical company endorses CI SADE weight sorters
27 September 2012 | By CI Precision
Actelion Pharmaceuticals Ltd, has endorsed CI SADE weight sorters...
GlaxoSmithKline plc announces changes to its Board and Committees
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
